The present invention provides an edible blended vegetable oil for reducing blood lipids and cholesterol. The trace elements in the edible blended vegetable oil include 15-300 mg/kg of polyphenols, 290-1700 mg/kg of β-sitosterol, 260-1500 mg/kg of campesterol, 150-1000 mg/kg of stigmasterol, 140-600 mg/kg of squalene, 50-160 mg/kg of parkerol, 40-120 mg/kg of γ-tocotrienol. The prepared edible blended vegetable oil of the present invention can achieve the effect of reducing blood lipids and cholesterol through a synergistic effect within the trace elements and a reasonable ratio within fatty acids. It is suitable for people with different health needs and has a broad market prospect and application value.

The present invention relates to a method of preparing a composition comprising ferulic acid. An aspect of the invention is a composition comprising hydrolysed wheat bran for use in the treatment or prevention of metabolic disease.

The present invention concerns the field of medications for the treatment of lesions and wounds of the skin and mucosa. The present invention relates to the use of a composition comprising a combination of a mucoadhesive component in the range from 0.05-20% by weight, an emollient component in the range from 0.02-20% by weight, hydrating and mucoprotective component i.e. hyaluronic acid in the range from 0.01-15% by weight and epithelizing component i.e. one or more amino acids in the range from 0.02-5% by weight in the treatment of epithelial lesions. The invention further comprises a composition comprising: carbomer (poly acrylic acid) in the range from 0.05% to 5%; sodium hyaluronate in the range from 0.01% to 15%; poloxamer (copolymers of ethylene oxide and propylene oxide) in the range from 0.1% to 15%; Oryza sativa extract in the range from 0.2% to 20%; and one or more amino acids in the range from 0.025% to 5%, wherein said percentages are by weight of the total weight of the product (w/w).

The present invention concerns the field of medications for the treatment of lesions and wounds of the skin and mucosa. The present invention relates to the use of a composition comprising a combination of a mucoadhesive component in the range from 0.05-20% by weight, an emollient component in the range from 0.02-20% by weight, hydrating and mucoprotective component i.e. hyaluronic acid in the range from 0.01-15% by weight and epithelizing component i.e. one or more amino acids in the range from 0.02-5% by weight in the treatment of epithelial lesions. The invention further comprises a composition comprising: carbomer (poly acrylic acid) in the range from 0.05% to 5%; sodium hyaluronate in the range from 0.01% to 15%; poloxamer (copolymers of ethylene oxide and propylene oxide) in the range from 0.1% to 15%; Oryza sativa extract in the range from 0.2% to 20%; and one or more amino acids in the range from 0.025% to 5%, wherein said percentages are by weight of the total weight of the product (w/w).

The present invention concerns the field of medications for the treatment of lesions and wounds of the skin and mucosa. The present invention relates to the use of a composition comprising a combination of a mucoadhesive component in the range from 0.05-20% by weight, an emollient component in the range from 0.02-20% by weight, hydrating and mucoprotective component i.e. hyaluronic acid in the range from 0.01-15% by weight and epithelizing component i.e. one or more amino acids in the range from 0.02-5% by weight in the treatment of epithelial lesions. The invention further comprises a composition comprising: carbomer (poly acrylic acid) in the range from 0.05% to 5%; sodium hyaluronate in the range from 0.01% to 15%; poloxamer (copolymers of ethylene oxide and propylene oxide) in the range from 0.1% to 15%; Oryza sativa extract in the range from 0.2% to 20%; and one or more amino acids in the range from 0.025% to 5%, wherein said percentages are by weight of the total weight of the product (w/w).

Disclosed herein are embodiments of therapeutic substances that contain solid sodium percarbonate for use in a bath, and packaging for the therapeutic substances. The solid sodium percarbonate can be dissolved in a liquid, such as water, to produce a hydrogen peroxide solution. Hydrogen peroxide solutions can be provide beneficial effects to a user. The titrated sodium percarbonate can be mixed with other chemicals/materials in a pre-made packaging for ease of storage and using with a bath.

Disclosed herein are embodiments of therapeutic substances that contain solid sodium percarbonate for use in a bath, and packaging for the therapeutic substances. The solid sodium percarbonate can be dissolved in a liquid, such as water, to produce a hydrogen peroxide solution. Hydrogen peroxide solutions can be provide beneficial effects to a user. The titrated sodium percarbonate can be mixed with other chemicals/materials in a pre-made packaging for ease of storage and using with a bath.

The present technology generally relates to compositions comprising at least one purified cannabinoid or a derivative thereof, and at least one functional fragrance. The present technology also generally relates to methods of using the compositions for, inter alia, improving sleep, for treating insomnia and/or related sleep disorders.

The present technology generally relates to compositions comprising at least one purified cannabinoid or a derivative thereof, and at least one functional fragrance. The present technology also generally relates to methods of using the compositions for, inter alia, improving sleep, for treating insomnia and/or related sleep disorders.

The present technology generally relates to compositions comprising at least one purified cannabinoid or a derivative thereof, and at least one functional fragrance. The present technology also generally relates to methods of using the compositions for, inter alia, improving sleep, for treating insomnia and/or related sleep disorders.